JP2010202664A5 - - Google Patents

Download PDF

Info

Publication number
JP2010202664A5
JP2010202664A5 JP2010130425A JP2010130425A JP2010202664A5 JP 2010202664 A5 JP2010202664 A5 JP 2010202664A5 JP 2010130425 A JP2010130425 A JP 2010130425A JP 2010130425 A JP2010130425 A JP 2010130425A JP 2010202664 A5 JP2010202664 A5 JP 2010202664A5
Authority
JP
Japan
Prior art keywords
factor viii
seq
amino acid
patient
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010130425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010202664A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010202664A publication Critical patent/JP2010202664A/ja
Publication of JP2010202664A5 publication Critical patent/JP2010202664A5/ja
Pending legal-status Critical Current

Links

JP2010130425A 2002-04-29 2010-06-07 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト Pending JP2010202664A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004501452A Division JP2005535588A (ja) 2002-04-29 2003-04-28 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2010202664A JP2010202664A (ja) 2010-09-16
JP2010202664A5 true JP2010202664A5 (enExample) 2011-07-21

Family

ID=29401334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004501452A Pending JP2005535588A (ja) 2002-04-29 2003-04-28 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
JP2010130425A Pending JP2010202664A (ja) 2002-04-29 2010-06-07 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004501452A Pending JP2005535588A (ja) 2002-04-29 2003-04-28 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト

Country Status (10)

Country Link
US (1) US8586538B2 (enExample)
EP (1) EP1497330B1 (enExample)
JP (2) JP2005535588A (enExample)
AT (1) ATE463514T1 (enExample)
AU (1) AU2003227687B2 (enExample)
CA (1) CA2484155C (enExample)
DE (1) DE60332011D1 (enExample)
DK (1) DK1497330T3 (enExample)
ES (1) ES2343681T3 (enExample)
WO (1) WO2003093313A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第viii因子の活性化を促進する抗体
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
BRPI0913374A2 (pt) * 2008-06-04 2015-11-24 Bayer Healthcare Llc muteínas fviii para tratamento de doença de von willebrand
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
JP5394864B2 (ja) * 2009-09-10 2014-01-22 アスモ株式会社 モータ
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
AU2011303916A1 (en) 2010-09-15 2013-03-21 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3164150B1 (en) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Modified von willebrand factor
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833848T3 (da) * 1995-06-12 2001-11-05 Sanquin Bloedvoorziening Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation
DK1095143T3 (da) * 1998-05-08 2009-01-05 Sanquin Bloedvoorziening Inhibitor til diagnosticering og behandling af patienter med hæmofili A
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität

Similar Documents

Publication Publication Date Title
JP2010202664A5 (enExample)
JP2013514992A5 (enExample)
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
JP2019196365A5 (enExample)
JP2018510132A5 (enExample)
JP2010534486A5 (enExample)
JP2008508859A5 (enExample)
JP2012136541A5 (enExample)
JP2017160222A5 (enExample)
JP2008535800A5 (enExample)
JP2008538564A5 (enExample)
JP2010505444A5 (enExample)
JP2015502346A5 (enExample)
JP2013520405A5 (enExample)
JP2005535588A5 (enExample)
WO2008092854A3 (en) Papillomavirus e2 polypeptide used for vaccination
JP2013510169A5 (enExample)
JP2008530245A5 (enExample)
JP2015522576A5 (enExample)
RU2015120804A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
JP2012255007A5 (enExample)
JP2008515446A5 (enExample)
JP2019507781A5 (enExample)
JP2015517489A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5